Liquid biopsy through circulating tumour cells (CTC) and circulating tumour DNA (ctDNA) analyses is becoming a promising approach for identifying mutation status, such as PIK3CA and ESR, which have sped up treatment decisions [15,16,17]. This evidence concerns the gene PIK3CA and neoplasm.